

TRUST BOTOX®

(Botulinum Toxin Type A)

CHRONIC MIGRAINE CAN BE DEVASTATING FOR PEOPLE LIKE ALI AND WE CAN HELP LESSEN THIS BURDEN¹⁻³

“I am continually letting down my friends, my family and colleagues... How can I plan anything or agree to anything?”

LOSS OF PRODUCTIVITY
IN THE WORKPLACE

57.4%

of people with chronic migraine miss at least 5 days of work or school over 3 months (n=520)¹

DISRUPTED
FAMILY LIFE

85.9%

of people with chronic migraine have a significantly reduced involvement or enjoyment in family activities (n=398)²

INCREASED DEPRESSION
AND ANXIETY

56.6%

of people with chronic migraine have comorbid depression and 48.4% have generalised anxiety disorder (n=1,476)³

BOTOX® (Botulinum toxin type A) Abridged Prescribing Information C: Clostridium botulinum toxin type A. **Indications:** Treatment of blepharospasm associated with dystonia including benign essential blepharospasm, hemifacial spasm & VIIIth nerve disorder in patients >12 yr; correction of strabismus in patients >12 yr; spasmodic torticollis (cervical dystonia) in adults; dynamic equinus foot deformity due to spasticity in paed cerebral palsy >2 yr. **Management of focal spasticity** including wrist & hand disability due to upper limb spasticity associated with stroke in adults; severe hyperhidrosis of the axillae not responding to topical treatment with antiperspirant or anticholinergics. **Prophylaxis of headaches** in adults with chronic migraine (headaches on at least 15 days/month at least 8 days are with migraine). **Treatment of urinary incontinence** due to neurogenic detrusor overactivity (NDO) assoc. with multiple sclerosis or spinal cord injury in adults with inadequate response or intolerant of anticholinergic medication. **Treatment of overactive bladder (OAB)** with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of an anticholinergic medication. **Temporary improvement in the appearance of upper facial rhytides (glabellar lines, crow's feet and forehead lines)** in adults. **Temporary treatment of glabellar lines** associated with comitators and/or procerus muscle activity in adults <65 yr. **D: Blepharospasm:** Initially, inj 1.25-2.5u into the medial & lateral orbicularis oculi of the upper lid & into the lateral pre-tarsal orbicularis oculi of the lower lid. Max: 100 u/12 wk. **Hemifacial spasm or VIIIth nerve disorders:** As for unilateral blepharospasm. Max: 200u/2 mth. **Strabismus:** Vertical muscles & horizontal strabismus of <20 prism diopters: 1.25-2.5u in any 1 muscle. Horizontal strabismus of 20-50 prism diopters: 2.5-5u in any 1 muscle. Persistent VIIIth nerve palsy of >1 mth: 1.25-2.5u in the medial rectus muscle. Max: 25u as single inj for any 1 muscle. **Cervical dystonia:** 95-360u. Initial dosing should begin at lowest effective dose. Max: 6u/kg/2mth. **Equinus foot deformity due to spasticity in paed cerebral palsy:** 4u/kg into each medial & lateral heads of the gastrocnemius muscle. Max: 200u at any single tx session. **Focal spasticity in adults:** Biceps brachii: 100-200u up to 4 sites; flexor digitorum profundus & flexor digitorum sublimis: 15-50u 1-2 sites; flexor carpi radialis: 15-60u 1-2 sites; flexor carpi ulnaris: 10-50u 1-2 sites; adductor pollicis & flexor pollicis longus: 20u 1-3 sites; gastrocnemius medial head: 75 units divided in 3 sites; gastrocnemius lateral head: 75 units divided in 3 sites; soleus: 75 units divided in 3 sites; tibialis posterior: 75 units divided in 3 sites; flexor hallucis longus: 50 units divided in 2 sites; flexor digitorum longus: 50 units divided in 2 sites; flexor digitorum brevis: 25 units in 1 site. **Hyperhidrosis of the axilla:** 50u intradermally to each axilla, evenly distributed in multiple sites 1-2 cm apart. **Chronic migraine:** 155u to 195u administered intramuscularly with 5u inj/ site. Inj should be divided across 7 specific head/neck muscle areas as specified in the PI. **NDO 200u inj** into detrusor muscle. **OAB:** 100 u inj into the detrusor muscle by cystoscopy. **Glabellar lines:** 4u /0.1 mL administered in each of 5 inj sites, 2 in each comitator muscle & 1 in procerus muscle. **Total dose:** 20u. **Crow's feet:** 2-6u/inj site bilaterally at 2 sites in the lateral aspect of orbicularis oculi. **Total dose for crow's feet:** 6-18 units per side. **Forehead lines:** 2-6u/inj site IM at 4 sites in frontalis muscle. **Total dose:** 8-24u. **CA:** Myasthenia gravis or Eaton-Lambert syndrome. **Infection** at proposed inj site. **For treatment of bladder dysfunction:** Acute UTI, acute urinary retention not routinely performing clean intermittent self-catheterization. **SP:** Inflammation at proposed inj site, excessive weakness or atrophy in the target muscles. **Antyotrophic lateral sclerosis, disorders causing peripheral neuromuscular dysfunction, patient at risk of angle-closure glaucoma.** Carefully perform cystoscopy (for bladder treatment). **Pregnancy, lactation, Children <12 yr, Elderly.** **AE:** Localised pain, tenderness &/or bruising; local weakness, UTI & urinary retention in bladder dysfunction patients. **Rarely,** skin rash (including erythema multiforme, urticaria & photosiform eruption), pruritus, allergic reaction. **DE:** Effects potentiated by aminoglycosides or other drugs that interfere with neuromuscular transmission; other muscle relaxants. **PIP:** Val 50u x 1%; 100u x 1%. Please see BOTOX® full prescribing information before prescribing. Further information is available upon request.

REFERENCES:

1. Khalil M, et al. J Headache Pain. 2014;15:54. 2. Lee MJ, et al. J Neurol Sci. 2016;363:51-54. 3. Ryan J, et al. J Clin Neurol. 2017;13(1):98-100.

For healthcare profession use only.



Allergan Singapore Pte Ltd

20 Passer Panjang Road, Mapletree Business City, West Building, #09-25, Singapore 117420.
Tel: +65 6747 7077 Fax: +65 6276 8157

SG-BTX-2150003 | January 2021

BOTOX®
Botulinum Toxin Type A